Cargando…

Robust real-world evidence: optimising disease-modifying treatments for multiple sclerosis

Detalles Bibliográficos
Autores principales:	McArthur, C., Daruwalla, C., Jayeskara, M., Brown, J. W. L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Journal Club
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10511364/ https://www.ncbi.nlm.nih.gov/pubmed/37698616 http://dx.doi.org/10.1007/s00415-023-11984-9

Ejemplares similares

Response to SARS-CoV-2 vaccination in multiple sclerosis patients on disease modifying therapies
por: Allman, M., et al.
Publicado: (2022)

B cell treatments for multiple sclerosis
por: McLauchlan, D., et al.
Publicado: (2017)

Continuous evolution of magnetic resonance imaging in multiple sclerosis
por: Tallantyre, E. C., et al.
Publicado: (2016)

Advances in biomarker research in multiple sclerosis
por: Butterworth, Sara E., et al.
Publicado: (2016)

Stem cell treatment for multiple sclerosis
por: Owen Pickrell, W., et al.
Publicado: (2016)

New rare genetic variants in multiple sclerosis
por: Harding, Katharine E., et al.
Publicado: (2018)

Early MRI predictors of prognosis in multiple sclerosis
por: Davda, Nikunj, et al.
Publicado: (2019)

Multiple sclerosis: early indicators of disease and assessing future risk
por: Willis, M. D., et al.
Publicado: (2020)

Advances in the use of stem cell transplants in the treatment of multiple sclerosis
por: Thomas, Rachel, et al.
Publicado: (2022)

A role for the Epstein–Barr virus in multiple sclerosis aetiology?
por: Hrastelj, J., et al.
Publicado: (2022)

Innovative biomarkers to predict unfavourable outcomes after initiating multiple sclerosis treatment
por: Kreft, Karim L., et al.
Publicado: (2022)

Preclinical retinal neurodegeneration in a model of multiple sclerosis: The Journal of Neuroscience 2012; 32(16):5585–5597
por: Mathur, Deepali, et al.
Publicado: (2012)

Genetics of disease severity in multiple sclerosis, Alzheimer’s disease, and Huntington’s disease: rejuvenating genome-wide association studies
por: Hrastelj, James, et al.
Publicado: (2017)

Multiple sclerosis and the risk of infection: considerations in the threat of the novel coronavirus, COVID-19/SARS-CoV-2
por: Willis, M. D., et al.
Publicado: (2020)

Journal Club: Efficacy of Tocilizumab in Early Systemic Sclerosis–Related Interstitial Lung Disease
por: Tiwari, Vivekanand, et al.
Publicado: (2021)

Hadza Color Terms Are Sparse, Diverse, and Distributed, and Presage the Universal Color Categories Found in Other World Languages
por: Lindsey, Delwin T., et al.
Publicado: (2016)

Ice bucket challenge bears fruit for amyotrophic lateral sclerosis
por: Hrastelj, James, et al.
Publicado: (2016)

Amyotrophic lateral sclerosis: an update on treatments from clinical trials
por: Wynford-Thomas, Ray, et al.
Publicado: (2023)

Disease-modifying treatments in Alzheimer’s disease
por: Edwards, Marc, et al.
Publicado: (2023)

Digital phenotyping and sociological perspectives in a Brave New World
por: Lovatt, Melanie, et al.
Publicado: (2017)

Socioeconomic status in neurological disorders: a modifiable risk factor?
por: Hrastelj, J., et al.
Publicado: (2022)

Physical activity as a risk factor for amyotrophic lateral sclerosis-findings from three large European cohorts
por: M, Hu, et al.
Publicado: (2020)

Eine Impfung gegen Multiple Sklerose?
por: Limmroth, Volker
Publicado: (2021)

Transmissible amyloid protein: evidence from iatrogenic CJD
por: Hu, Mo, et al.
Publicado: (2018)

Idiopathic rapid eye movement sleep behaviour disorder: a potential gateway to the development of disease-modifying treatments in neurodegenerative disorders
por: Peall, K. J., et al.
Publicado: (2016)

Recent evidence on perception and esthetic appreciation: The role of value and expertise in canon formation
por: Consoli, Gianluca
Publicado: (2014)

Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval
por: Loncharich, Michael F., et al.
Publicado: (2022)

The exposome in respiratory diseases: multiple preventable risk factors from early life to adulthood
por: Savouré, Marine, et al.
Publicado: (2023)

New Consensus on the Management of Barrett's Dysplasia and Early Stage Esophageal Adenocarcinoma: Limited Evidence, but Best Available Guidance (Gastroenterology 2012;143:336-346)
por: Jo, Yunju
Publicado: (2012)

Beta-lactam antibiotic offers neuroprotection in a spinal muscular atrophy model by multiple mechanisms: Experimental Neurology 2011; 229: 214–225
por: Bhatia, Sonu
Publicado: (2011)

Significance of Persistent Nondysplasia Over Multiple Endoscopic Surveillance in Risk Stratification of Patients With Barrett's Esophagus (Gastroenterology 2013;145:548-553, e1)
por: Kim, Jeong Hwan
Publicado: (2013)

Intensivmedizinische Studien aus 2016/2017
por: Reuß, C. J., et al.
Publicado: (2017)

Fokus Neurologische Intensivmedizin 2021/2022: Zusammenfassung ausgewählter intensivmedizinischer Studien
por: Michalski, D., et al.
Publicado: (2022)

Fokus neurologische Intensivmedizin. Intensive Care Studies from 2020/2021
por: Michalski, D., et al.
Publicado: (2021)

Fokus Neurologische Intensivmedizin: Intensivmedizinische Studien aus 2019/2020
por: Michalski, D., et al.
Publicado: (2020)

Fokus Beatmung, Sauerstofftherapie und Weaning: Intensivmedizinische Studien aus 2019/2020
por: Fiedler, M. O., et al.
Publicado: (2020)

Fokus Beatmung, Sauerstofftherapie und Weaning: Intensivmedizinische Studien aus 2020/2021
por: Fiedler, Mascha O., et al.
Publicado: (2021)

Fokus Beatmung, Sauerstofftherapie und Weaning 2021/2022: Zusammenfassung ausgewählter intensivmedizinischer Studien
por: Fiedler, M. O., et al.
Publicado: (2023)

Fokus allgemeine Intensivmedizin. Intensivmedizinische Studien aus 2020/2021
por: Dietrich, M., et al.
Publicado: (2021)

A NOD to zebrafish models of inflammatory bowel disease pathogenesis
por: Allen, Irving C.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_8lnhm0agoe13bc3r3v9df28o62